Amussen Hunsaker Associates LLC Viking Therapeutics, Inc. Transaction History

Amussen Hunsaker Associates LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$2.72 - $9.4 $5,440 - $18,800	-2,000 Reduced 8.34%	21,980 $206,000
Q2 2021 Aug 17, 2021	BUY	$5.19 - $6.73 $124,456 - $161,385	23,980 New	23,980 $145,000
Q1 2021 May 18, 2021	SELL	$5.74 - $9.67 $109,232 - $184,020	-19,030 Closed	0 $0
Q3 2020 Nov 23, 2020	BUY	$5.73 - $8.11 $4,584 - $6,488	800 Added 4.39%	19,030 $111,000
Q2 2020 Aug 17, 2020	SELL	$4.35 - $8.08 $33,234 - $61,731	-7,640 Reduced 29.53%	18,230 $131,000
Q4 2018 Feb 19, 2019	SELL	$7.16 - $16.21 $22,554 - $51,061	-3,150 Reduced 10.85%	25,870 $198,000
Q3 2018 Nov 16, 2018	BUY	$9.7 - $19.65 $162,688 - $329,569	16,772 Added 136.94%	29,020 $318,000
Q2 2018 Aug 16, 2018	BUY	$3.88 - $12.74 $776 - $2,548	200 Added 1.66%	12,248 $116,000
Q1 2018 May 15, 2018	BUY	$4.11 - $6.93 $5,219 - $8,801	1,270 Added 11.78%	12,048 $53,000
Q4 2017 Feb 16, 2018	BUY	$1.74 - $4.34 $18,753 - $46,776	10,778	10,778 $44,000

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.95B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Amussen Hunsaker Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Amussen Hunsaker Associates LLC with notifications on news.